Australia markets close in 3 hours 54 minutes

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
45.18+5.51 (+13.89%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close39.67
Open38.54
Bid43.15 x 900
Ask45.11 x 1200
Day's range38.52 - 45.62
52-week range25.31 - 141.01
Volume2,131,207
Avg. volume1,759,400
Market cap5.776B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-14.64
Earnings date25 Feb 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est80.20
  • Motley Fool

    Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu

    Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.

  • Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
    Zacks

    Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More

    The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).

  • Why Vir Biotechnology Stock Is Falling Today
    Motley Fool

    Why Vir Biotechnology Stock Is Falling Today

    Shares of Vir Biotechnology (NASDAQ: VIR) are dropping sharply on Thursday despite the drugmaker not reporting any news. Goldman Sachs analyst Paul Choi lowered his price target on Vir Biotechnology from $61 to $59. As a reminder, Vir Biotechnology and its partner GlaxoSmithKline are taking part in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program, an initiative led by the U.S. National Institutes of Health (NIH).